Advanced Neuropsychological Treatment Services, Sydney, Australia.
Department of Psychology, Macquarie University, Sydney, Australia.
Appl Neuropsychol Adult. 2022 Nov-Dec;29(6):1511-1521. doi: 10.1080/23279095.2021.1895791. Epub 2021 Apr 8.
Accurate screening for cognitive impairment in alcohol and other drug (AOD) services would help to identify individuals who may need supports to obtain the greatest benefit from substance use disorder (SUD) treatment. At present there is no screening measure that has been developed specifically to detect cognitive impairment in a SUD population. This study examines the psychometric properties of the Brief Executive-function Assessment Tool (BEAT), which was specifically designed for this purpose. This study involving 501 individuals with SUD and 145 normal control participants established internal consistency ( = 646; 0.734), interrater ( = 60; 0.994), and test-retest reliability ( = 177; 0.845), and construct (all correlations ≤ 0.05), and criterion ( = 467; ANCOVA < 0.001) validity. Test operating characteristics ( = 500; 87% sensitivity, 71% specificity, 21% , and 99% ) were also established relative to an independent criterion variable made up of three established performance-based neuropsychological tests. Findings support the reliability and validity of the BEAT as a screening measure of executive function impairment with high sensitivity and a low rate of false negatives.
准确的认知障碍筛查有助于识别那些可能需要支持以从物质使用障碍（SUD）治疗中获得最大益处的个体。目前，还没有专门开发用于检测 SUD 人群认知障碍的筛查措施。本研究检验了专门为此目的设计的 Brief Executive-function Assessment Tool（BEAT）的心理测量特性。这项涉及 501 名 SUD 患者和 145 名正常对照组参与者的研究确立了其内部一致性（ = 646；0.734）、评分者间一致性（ = 60；0.994）和重测信度（ = 177；0.845），并建立了结构效度（所有相关系数均 ≤ 0.05）和标准效度（ = 467；ANCOVA < 0.001）。相对于由三个既定的基于表现的神经心理学测试组成的独立标准变量，测试操作特性（ = 500；87%的敏感性，71%的特异性，21%的假阴性率和 99%的假阳性率）也得到了确立。研究结果支持 BEAT 作为一种具有高敏感性和低假阴性率的执行功能障碍筛查措施的可靠性和有效性。
